Table 2 Baseline demographic and clinical characteristics of the study population*
Group A (Control) | Group B (Intervention) | P value** | |
|---|---|---|---|
Subjects (n) | 12 | 10 | |
Age (years) | 55.4 ± 12.6 | 60.0 ± 11.3 | 0.385 |
Sex (male: female)*** | 3:9 | 4:6 | 0.652 |
Duration of Diabetes (years) | 16.4 ± 7.9 | 17.6 ± 9.0 | 0.745 |
Body weight (Kg) | 78.1 ± 17.4 | 71.8 ± 20.7 | 0.444 |
BMI (Kg/m2) | 30.2 ± 6.0 | 28.4 ± 6.4 | 0.552 |
A1C (%) | 9.6 ± 1.6 | 9.0 ± 0.8 | 0.309 |
eGFR (ml/min) | 75.2 ± 29.0 | 55.5 ± 30.5 | 0.137 |
Insulin treatment duration (years) | 11.2 ± 7.4 | 8.4 ± 6.0 | 0.344 |
Entry insulin dose (IU/day) | 66.1 ± 19.0 | 71.7 ± 47.2 | 0.709 |
Entry insulin dose (IU/Kg/day) | 0.9 ± 0.3 | 1.0 ± 0.4 | 0.641 |
Basal insulin dose (IU/day) | 54.3 ± 13.3 | 56.8 ± 32.3 | 0.811 |
Bolus insulin dose (IU/day) | 11.8 ± 12.5 | 14.9 ± 18.5 | 0.640 |